The COVID-19 pandemic showed how poorly prepared we were to deal with a newly-emerging respiratory virus. Antiviral drugs with the appropriate spectrum of activity can protect against a new pandemic threat until a vaccine can be developed and deployed. Drugs should be suitable for post-exposure prophylaxis or treatment of mild disease, possess oral activity with a good safety profile, have low cost of goods, and be easy to deliver and suitable for combination. The global research community must act collectively to generate a toolkit of antiviral agents covering a number of viral families. Scientists from many sectors – industry, academia, non-profits – will be involved, working in a multidisciplinary effort. This presentation provides a perspective on pandemic preparedness, the approaches that are being taken to tackle this problem, and the need to ensure equitable access to any drugs that are developed.
Friday, January 6, 2023, 12:00 PM ET
- On the day of the event, visit the My Dashboard page to attend virtually.